Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI-1808 first-in-human dose-escalation study alone and with Keytruda in advanced malignancies
2023-509847-29-00Phase 2Authorised
- Sponsor
- BioInvent International
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of BI-1808 in Nonhematologic neoplasms, advanced cancer, cutaneous T-cell lymphoma (CTCL) and 1 more (2 arms), sponsored by BioInvent International. Primary endpoint: Safety and tolerability. Planned start Apr 2020; status: authorised.
02
Drugs
BI-1808
03
Conditions
Nonhematologic neoplasmsadvanced cancercutaneous T-cell lymphoma (CTCL)ovarian cancer
Beyond the preview
Go deeper on 2023-509847-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509847-29-00.